Literature DB >> 23625683

Normalized transcranial Doppler velocities, stroke prevention and improved pulmonary function after stem cell transplantation in children with sickle cell anemia.

M Mynarek1, C Bettoni da Cunha Riehm, F Brinkmann, K Weißenborn, M Tell-Lüersen, H-G Heuft, B Maecker-Kolhoff, K-W Sykora.   

Abstract

BACKGROUND: Abnormal transcranial Doppler velocities (TCD) indicate an increased risk of stroke in patients with sickle cell anemia (SCA) and require regular blood transfusions. Hematopoietic stem cell transplantation (HSCT) is under discussion as an alternative to chronic transfusion in these patients. PATIENTS AND METHODS: This retrospective analysis includes 9 patients with SCA undergoing HSCT at a single center in Germany. Special focus was given to the neurologic follow-up and to the results of TCD studies.
RESULTS: High risk of stroke or previous stroke was an HSCT-indication in 8 of 9 patients, although most patients had more than one indication for HSCT. TCD was normalized in all 5 patients after HSCT in whom this test was available. None of the patients developed a stroke after HSCT. No further strokes occurred even in patients that experienced recurrent strokes during chronic transfusion before HSCT. 2 of the 9 patients received a 10/10 HLA-matched unrelated donor graft, the others matched related grafts.All patients were alive, free of SCA symptoms and transfusion-independent with stable chimerism 3-11 years after HSCT. Pulmonary function tests normalized in 1 patient with severe sickle cell lung disease.
CONCLUSION: HSCT is able to prevent stroke in patients with SCA. Its perspectives and limitations should be discussed early during the treatment of a patient with complicated SCA. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23625683     DOI: 10.1055/s-0033-1333754

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  5 in total

Review 1.  Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.

Authors:  Courtney D Fitzhugh; Allistair A Abraham; John F Tisdale; Matthew M Hsieh
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-29       Impact factor: 3.722

Review 2.  Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Authors:  Courtney D Fitzhugh; Emmanuel J Volanakis; Ombeni Idassi; Josh A Duberman; Michael R DeBaun; Debra L Friedman
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

Review 3.  Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease.

Authors:  Emily Limerick; Allistair Abraham
Journal:  J Clin Med       Date:  2022-07-03       Impact factor: 4.964

Review 4.  Update of hematopoietic cell transplantation for sickle cell disease.

Authors:  Mark C Walters
Journal:  Curr Opin Hematol       Date:  2015-05       Impact factor: 3.284

Review 5.  Cellular therapy for sickle cell disease.

Authors:  Allistair Abraham; David A Jacobsohn; Catherine M Bollard
Journal:  Cytotherapy       Date:  2016-07-14       Impact factor: 5.414

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.